Physician

Christopher Lake Littlejohn, M.D.

According to 2025 Medicare claims, Christopher Littlejohn, M.D. (NPI: 1952764318) practices hematology/oncology in the Longview, TX market, with the plurality of this provider's patient population coming from Gregg, TX. This provider's primary affiliated billing organization is TEXAS ONCOLOGY PA (NPI: 1811944101; TIN: 752131429) and primary practice location at 75601-4717.

Littlejohn's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 720 traditional Medicare patients, billed 181,529 HCPCS/CPT codes, and received $2,730,883 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 855 prescription claims across 167 beneficiaries totaling $909,088 in drug costs, led by Erleada (Apalutamide). 2020 DME data shows 12 claims. Open Payments data shows 61 records totaling $1,365. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider has fewer than 5 years of reported Medicare Part B carrier billing data, so a reliable trend cannot be assigned. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $1,369 to $909,088. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	12	4,981	$38,533
2023	303	62,987	$951,008
2024	720	181,529	$2,730,883

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	N/R	N/R	N/R
2016	N/R	24	$1,369
2017	50	176	$13,816
2018	43	255	$29,217
2019	35	188	$19,154
2020	23	114	$8,917
2021	N/R	15	$113
2022	N/R	N/R	N/R
2023	27	68	$56,154
2024	167	855	$909,088

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	25	$1,094
2019	N/R	12	$10,195
2020	N/R	12	$10,419
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	157	334	$96
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	125	363	$12
80053	Blood test, comprehensive group of blood chemicals	166	391	$10
36415	Insertion of needle into vein for collection of blood sample	203	656	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	195	583	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Erleada	Apalutamide	22	740	$313,508
Venclexta	Venetoclax	12	326	$147,137
Eliquis	Apixaban	87	2,725	$52,705
Xarelto	Rivaroxaban	18	698	$12,455
Abiraterone Acetate	Abiraterone Acetate	11	330	$5,616

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	61	$1,365	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Christopher Lake Littlejohn, M.D.?

Tedicare shows public-source Medicare data for Christopher Lake Littlejohn, M.D. (NPI 1952764318), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Christopher Lake Littlejohn, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Christopher Lake Littlejohn, M.D.?

Christopher Lake Littlejohn, M.D. is linked to TEXAS ONCOLOGY PA (billing NPI 1811944101) in the available physician profile data.

Does Christopher Lake Littlejohn, M.D. have Open Payments data?

Christopher Lake Littlejohn, M.D. has 61 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.